['hiv-1 infection']
['abc/dtg/3tc', 'b/f/taf', 'abc/dtg/3tc placebo', 'b/f/taf placebo']

        Key Inclusion Criteria:

          -  Estimated glomerular filtration rate ≥ 50 mL/min (≥ 0.83 mL/sec).

          -  Currently receiving an antiretroviral regimen of DTG + ABC/3TC, or ABC/DTG/3TC FDC for
             ≥ 3 months prior to the screening visit.

          -  HIV ribonucleic acid (RNA) < 50 copies/mL at the screening visit.

          -  Currently on a stable regimen for ≥ 3 months preceding the screening visit with
             documented plasma HIV-1 RNA < 50 copies/mL for ≥ 3 months preceding the screening
             visit (or undetectable HIV-1 RNA level according to the local assay being used if the
             limit of detection is ≥ 50 copies/mL).

          -  Have no documented or suspected resistance to emtricitabine (FTC), tenofovir (TFV),
             DTG, ABC or 3TC.

        Key Exclusion Criteria:

          -  Current alcohol or substance use judged by the Investigator to potentially interfere
             with subject study compliance.

          -  Active tuberculosis infection.

          -  Individuals experiencing decompensated cirrhosis (eg, ascites, encephalopathy, or
             variceal bleeding).

          -  Females who are pregnant.

          -  Females who are breastfeeding.

          -  Acute hepatitis in the 30 days prior to study entry.

          -  Chronic Hepatitis B Virus (HBV) infection.

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      